18 and older, male only, with Metastatic Castration-resistant Prostate Cancer or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With ResponsePrimary· From the date of first dose administration to the end of treatment (maximum exposure: 168 days)
Response was defined as Prostate-Specific Antigen (PSA) decline of ≥ 50% (PSA50) and/or radiographic objective response of Complete Response (CR) or Partial Response (PR) per Prostate Cancer Working Group 3 (PCWG3) Criteria. The number of participants with response shows participants with any one or combination of these response types.
* CR: Disappearance of all extranodal target lesions. All pathological lymph nodes must have decreased to \< 10 millimeters (mm) in short axis
* PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum of diame
Group
Value
95% CI
SRF617 + Etrumadenant + Zimberelimab
0
Number of Participants With Adverse Events (AEs)Primary· From date of first dose until 90 days after the last dose of treatment (maximum treatment exposure: 168 days)
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious Adverse Events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless
Group
Value
95% CI
SRF617 + Etrumadenant + Zimberelimab
15
Number of Participants With PSA50 ResponseSecondary· From the date of first dose administration to the end of treatment (maximum exposure: 168 days)
PSA50 response is defined as a confirmed PSA decrease from Baseline of 50% or more based on 2 consecutive assessments measured 3 to 4 weeks apart.
Group
Value
95% CI
SRF617 + Etrumadenant + Zimberelimab
0
Number of Participants With Symptomatic Skeletal Events (SSEs)Secondary· From date of first dose until 90 days after the last dose of treatment (maximum treatment exposure: 168 days)
Number of participants with SSEs per PCWG3 criteria, defined as symptomatic fracture, radiation or surgery to bone, or spinal cord compression, is reported.
Group
Value
95% CI
SRF617 + Etrumadenant + Zimberelimab
4
Adverse events — posted to ClinicalTrials.gov
Time frame: From date of first dose until 90 days after the last dose of treatment (maximum treatment exposure: 168 days).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07288359 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and
· Phase 1, PHASE2
· recruiting
NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (
· Phase 1
· recruiting
NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic
· Phase 3
· recruiting
NCT07189403 — A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist
· Phase 1
· recruiting
Other Coherus Oncology, Inc. trials
Trials by the same sponsor.
NCT06389526 — A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
· Phase 1
· not yet recruiting
NCT05757492 — Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
· Phase 1
· terminated
NCT05635643 — Study of CHS-114 in Participants With Advanced Solid Tumors
· Phase 1
· recruiting
NCT05359861 — Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
· Phase 2
· completed
NCT04662892 — An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
· unknown
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Coherus Oncology, Inc.
Last refreshed: 8 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177770.